当前位置：
X-MOL 学术
›
Bioconjugate Chem.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Ultrasound-Augmented Phase Transition Nanobubbles for Targeted Treatment of Paclitaxel-Resistant Cancer.
Bioconjugate Chemistry ( IF 4.0 ) Pub Date : 2020-07-06 , DOI: 10.1021/acs.bioconjchem.0c00364 Yi Zhu 1, 2 , Guonan Zhang 3 , Meiying Li 4 , Lang Ma 1 , Jianming Huang 4 , Li Qiu 1
Bioconjugate Chemistry ( IF 4.0 ) Pub Date : 2020-07-06 , DOI: 10.1021/acs.bioconjchem.0c00364 Yi Zhu 1, 2 , Guonan Zhang 3 , Meiying Li 4 , Lang Ma 1 , Jianming Huang 4 , Li Qiu 1
Affiliation
|
Paclitaxel (PTX) resistance in most epithelial ovarian cancers (EOCs) with increasing membrane expression of mucin 16 (MUC16) is mediated by the Toll-like receptor-myeloid differentiation factor 2/myeloid differentiation factor 88 (TLR4-MD2/MyD88) signaling pathway. 6-Shogaol (6S), an α,β-unsaturated carbonyl compound with lipophilic property, can block PTX-induced formation of the TLR4-MD2 complex that activates the MyD88/NF-κB signaling pathway. Herein, to improve the effectiveness of 6S, augment the sensibility of PTX, and enhance the targeting ability of PTX-resistant cancer therapies, we report a class of 6S-loaded phase transition nanobubbles conjugated with the MUC16 antibody (6S@NBs-MUC16A), which can enhance the sensitivity of PTX to EOC cells through ultrasound-controlled targeted-delivery of 6S. The 6S@NB-MUC16A could enhance the targeting efficiency and organizational distribution of 6S in MyD88+ EOC area, and the 1 MHz ultrasound can be used as an initiator to trigger the “explosion” of nanobubbles and promote the 6S release. Furthermore, in vivo assessment results indicate that ultrasound-augmented 6S@NB-MUC16A can significantly improve the response of EOC to PTX and the inhibition ratio of tumor growth compared to the control-treated with PTX alone, and exhibit less toxicity to the critical organs. The ultrasound-augmented 6S@NB-MUC16A with less cytotoxicity could be a potentially useful nanosystem to surmount PTX resistance in EOC, which provides potential possibilities for the applications in the biological field.
中文翻译：
超声增强相变纳米气泡对紫杉醇耐药癌症的靶向治疗。
在大多数黏膜16（MUC16）膜表达增加的上皮性卵巢癌（EOC）中，紫杉醇（PTX）耐药性是由Toll样受体-髓系分化因子2 /髓系分化因子88（TLR4-MD2 / MyD88）信号传导途径介导的。6-Shogaol（6S）是一种具有亲脂性的α，β-不饱和羰基化合物，可以阻止PTX诱导的TLR4-MD2复合物的形成，该复合物激活MyD88 /NF-κB信号通路。在本文中，为了提高6S的效力，增强PTX的敏感性并增强PTX耐药性癌症治疗的靶向能力，我们报道了一类与MUC16抗体偶联的6S负载相变纳米气泡（6S @ NBs-MUC16A） ，可以通过6S的超声控制靶向递送来增强PTX对EOC细胞的敏感性。+ EOC区域，并且1 MHz超声可以用作引发剂来触发纳米气泡的“爆炸”并促进6S释放。此外，体内评估结果表明，与单独使用PTX的对照组相比，超声增强的6S @ NB-MUC16A可以显着改善EOC对PTX的反应和肿瘤生长的抑制率，并且对关键器官的毒性较小。具有较小细胞毒性的超声增强6S @ NB-MUC16A可能是克服EOC中PTX耐药性的潜在有用纳米系统，这为生物领域的应用提供了潜在的可能性。
更新日期：2020-07-06
中文翻译：
超声增强相变纳米气泡对紫杉醇耐药癌症的靶向治疗。
在大多数黏膜16（MUC16）膜表达增加的上皮性卵巢癌（EOC）中，紫杉醇（PTX）耐药性是由Toll样受体-髓系分化因子2 /髓系分化因子88（TLR4-MD2 / MyD88）信号传导途径介导的。6-Shogaol（6S）是一种具有亲脂性的α，β-不饱和羰基化合物，可以阻止PTX诱导的TLR4-MD2复合物的形成，该复合物激活MyD88 /NF-κB信号通路。在本文中，为了提高6S的效力，增强PTX的敏感性并增强PTX耐药性癌症治疗的靶向能力，我们报道了一类与MUC16抗体偶联的6S负载相变纳米气泡（6S @ NBs-MUC16A） ，可以通过6S的超声控制靶向递送来增强PTX对EOC细胞的敏感性。+ EOC区域，并且1 MHz超声可以用作引发剂来触发纳米气泡的“爆炸”并促进6S释放。此外，体内评估结果表明，与单独使用PTX的对照组相比，超声增强的6S @ NB-MUC16A可以显着改善EOC对PTX的反应和肿瘤生长的抑制率，并且对关键器官的毒性较小。具有较小细胞毒性的超声增强6S @ NB-MUC16A可能是克服EOC中PTX耐药性的潜在有用纳米系统，这为生物领域的应用提供了潜在的可能性。
京公网安备 11010802027423号